Drug Procurement

Drug procurement in government is the structured acquisition of medicines, vaccines, biologicals, and pharmaceutical supplies by central ministries, state health departments, PSUs, and autonomous health bodies through competitive tenders governed by GFR 2017 and state-specific drug procurement policies.

What is Drug Procurement?

Government drug procurement operates at two levels. At the central level, the Ministry of Health and Family Welfare procures for national programmes (TB, HIV, malaria, vaccines under the Universal Immunisation Programme), CGHS facilities, ESI hospitals, and central autonomous institutions like AIIMS. Central drug procurement often uses multi-year Rate Contracts for Medicines.

At the state level, state health departments run their own procurement through agencies such as Tamil Nadu Medical Services Corporation (TNMSC), Rajasthan Medical Services Corporation (RMSC), and GDSC Gujarat. These state corporations aggregate demand from thousands of government health facilities and conduct bulk annual tenders, achieving economies of scale.

Key drug procurement characteristics:

• Pharmacopoeia Compliance (IP, USP, BP) mandatory for all pharmaceutical products
• Drug Manufacturing Licence under Drugs and Cosmetics Act required from manufacturers
• WHO-GMP or Schedule M compliance for manufacturing facilities
• CDSCO approvals for formulations
• Batch testing at approved laboratories before supply acceptance
• Cold chain requirements for vaccines and temperature-sensitive biologicals

Evaluation is L1 among pharmacopoeially and technically compliant bidders. Quality certificates and batch testing are enforced post-award.

Why Drug Procurement matters for Indian government suppliers

Government drug procurement represents a massive, consistent demand pipeline. A single state drug tender may cover Rs 50-500 crore in medicines, providing pharmaceutical manufacturers with multi-year supply contracts. The AMRIT Pharmacy and Jan Aushadhi Programme create additional government-led procurement channels at subsidised prices.

Example

Rajasthan Medical Services Corporation issues an annual tender for 120 essential medicines on its state procurement portal. A pharmaceutical manufacturer qualifying with WHO-GMP certification, valid Drug Manufacturing Licence, and pharmacopoeia-compliant formulations submits bids for 35 molecules where it is competitive. It wins 18 drug items as L1 bidder, securing a Rs 22 crore annual supply contract for government hospitals across Rajasthan.

Frequently Asked Questions

What quality standards are mandatory for government drug tenders?

All drugs must comply with the Indian Pharmacopoeia (IP) or equivalent (USP, BP) for formulation standards. Manufacturing facilities must hold a valid Drugs and Cosmetics Act licence and comply with Schedule M (GMP). Central and state procurement agencies may require additional WHO-GMP certification for competitive tenders.

How does the government ensure drug quality post-procurement?

State drug procurement agencies conduct random batch sampling from delivered lots and send samples to government or approved private laboratories for pharmacopoeia testing. Batches failing quality tests are rejected and the supplier must replace the supply. Repeated quality failures lead to blacklisting.

Can MSMEs participate in drug procurement?

Yes. Pharmaceutical MSMEs with valid drug manufacturing licences and WHO-GMP certification can compete directly. Many essential medicines in government tenders are generic formulations where small manufacturers are cost-competitive. MSME status provides EMD exemption on central tenders.

What is the difference between central and state drug procurement?

Central procurement covers national health programme drugs, CGHS, ESI, and AIIMS. State procurement covers government hospitals, PHCs, CHCs, and state health scheme beneficiaries within the state. Both operate independently; a manufacturer can supply to both simultaneously.